Novartis' troubled Alcon unit recalls eye drops for sterility, potency problems

F. Michael Ball, the former Hospira CEO who took over the top spot at Novartis' ($NVS) troubled Alcon unit last month, already had plenty on his to-do list. The division's sales are way off, it's squeezing manufacturing costs and it's dealing with a recall in Japan. Now, Ball has another recall to contend with. More from FiercePharmaManufacturing